TRAJENTA®

Linagliptin

 

TRAJENTA®

Mechanism of Action

How does TRAJENTA® work?

TRAJENTA® is a ‘gliptin’ and an inhibitor of the enzyme DPP-4, an enzyme which is involved in the inactivation of the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both incretin hormones are involved in the physiological regulation of glucose homeostasis and these hormones are rapidly degraded by the enzyme DPP-4.1 TRAJENTA® selectively inhibits DPP-4, which leads to a glucose-dependent increase in insulin secretion and a reduction in glucagon secretion thus resulting in an overall improvement in glucose homeostasis.1 DPP-4 inhibitors prolong the action of GLP-1 and GIP by working in a glucose-dependent way.2,3

Quick links

Quick links
Up icon

Increase glucose dependent insulin secretion leading to increased glucose utilisation by muscle and adipose tissue.

Down icon

Increase glucose dependent glucagon suppression leading to decreased hepatic glucose release improving overall glucose control.

TRAJENTA® is excreted primarily via the bile.

Only 5% of TRAJENTA® is excreted through the kidney and it can therefore be used at any stage of renal function.1

Proportions of medication excreted via the kidney

Infographic comparison chart of TRAJENTA® (linagliptin) and other drugs excreted via the kidney
TRAJENTA® (linagliptin) dose and administration

Simple dosing and administration

Patients and practitioners can harness the simplicity of one dose, once daily, for adult patients with type 2 diabetes.1†
Read more
TRAJENTA® (linagliptin) safety profile

Proven safety and efficacy via clinical studies

Cardiovascular (CV) safety is an important concern when managing adult patients with type 2 diabetes. TRAJENTA® demonstrated a safety profile across a broad range of T2D patients in 2 CVOTs including over 13,000 patients.8-11*
Read more
TRAJENTA® (linagliptin) patient profiles

How can TRAJENTA® help your adult patients with Type 2 diabetes?

A range of hypothetical scenarios using fictitious characters to demonstrate how TRAJENTA® can help your adult patients with type 2 diabetes.
Read more

Footnote

Footnote
  • *CARMELINA® and CAROLINA® included 6,979 and 6,033 patients respectively.
  • †Sulphonylureas and insulin are known to cause hypoglycaemia. Therefore, caution is advised when linagliptin is used in combination with a sulphonylurea and/or insulin. A dose reduction of the sulphonylurea or insulin may be considered (TRAJENTA® SmPC).
References
  1. TRAJENTA® (linagliptin) Summary of Product Characteristics. SmPCs available at EMC: www.medicines.org.uk (GB) and https://www.emcmedicines.com/en-GB/northernireland/ (NI).
  2. Drucker DJ. Expert Opin Invest Drugs 2003;12:87-100.
  3. Ahrén B. Curr Diab Rep 2003;3:365-372.
  4. Sitagliptin Summary of Product Characteristics. SmPCs available at EMC: www.medicines.org.uk (GB) and www.emcmedicines.com/en-GB/northernireland/ (NI).
  5. Vildagliptin Summary of Product Characteristics. SmPC available at EMC: www.medicines.org.uk (GB).
  6. Saxagliptin Summary of Product Characteristics. SmPCs available at EMC: www.medicines.org.uk (GB) and www.emcmedicines.com/en-GB/northernireland/ (NI).
  7. Alogliptin Summary of Product Characteristics. SmPCs available at EMC: www.medicines.org.uk (GB) and www.emcmedicines.com/en-GB/northernireland/ (NI).
  8. Rosenstock J et al. JAMA 2019;321(1):69–79.
  9. Rosenstock J, et al. Cardiovasc Diabetol. 2018;17:39.
  10. Marx N, et al. Diab Vasc Res. 2015;12:164–74.
  11. Rosenstock J, et al. JAMA. 2019;322(12):1155–1166.

PC-GB-105687 V2

September 2022

Reporting adverse events

Adverse events should be reported. Reporting form and information can be found atwww.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.